Abstracts tagged "biosimilars and infliximab"

Abstract Number: 203 • 2019 ACR/ARP Annual Meeting
Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures
Cristiano S. Moura ¹, Jeffrey Curtis ², Denis Choquette ³, Gilles Boire ⁴, Vivian Bykerk ⁵, Carter Thorne ⁶, Walter P. Maksymowych ⁷, Peter L. Lakatos ⁸, Larry Svenson ⁹, Laura Targownik ¹⁰, Waqqas Afif ⁸ and Sasha Bernatsky¹¹, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York City, NY, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁸McGill University, Montreal, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In North America, biosimilars were approved only relatively recently, and real-world data are few. We described users of infliximab in the US, comparing patient…
Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Guro Løvik Goll¹, Nils Bolstad², Ines Iria^3,4, Rolf Klaasen⁵, Kristin Kaasen Jørgensen⁶, Inge C Olsen⁷, Ana Valido⁸, Maria J Saavedra⁹, João E. Fonseca¹⁰, Merete Lorentzen¹¹, Cato Mork¹², Knut EA Lundin¹³, David J Warren¹⁴, Espen A. Haavardsholm¹⁵, Jorgen Jahnsen¹⁶, Tore Kvien¹⁵ and João Gonçalves¹⁷, ¹Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ³Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, ⁴iMed- Research Institute for medicines, Lisbon, Portugal, ⁵Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ⁶Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹¹Dept of Dermatology, Rikshospitalet, Oslo, Norway, ¹²Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ¹³Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, ¹⁴Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ¹⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ¹⁷Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
Abstract Number: 462 • 2017 ACR/ARHP Annual Meeting
ABP 710: Matching Critical Biological Functions with Infliximab
Robert Sandrock¹, Palanisamy Kanakaraj² and Scott Kuhns¹, ¹Amgen, Inc., Thousand Oaks, CA, ²Amgen, Inc., Cambridge, MA
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab, a recombinant chimeric monoclonal antibody that binds tumor necrosis factor alpha (TNFa) and inhibits…
Abstract Number: 2466 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB2 or Reference Infliximab
Josef S. Smolen¹, Jung-Yoon Choe², Edward C. Keystone³, Young Hee Rho⁴, Younju Lee⁴ and Sora Lee⁴, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Department of Internal Medicine, Catholic university of Daegu School of Medicine, Daegu, Korea, Republic of (South), ³Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: Based on the totality of evidence, SB2 has shown to be similar with reference infliximab (INF) and has been approved as a biosimilar by…
Abstract Number: 951 • 2016 ACR/ARHP Annual Meeting
A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Bente Glintborg¹, Inge Juul Sørensen², Dorte Vendelbo Jensen², Niels Steen Krogh³, Anne Gitte Loft⁴, Jakob Espesen², Jimmi Olsen², Oliver Hendricks⁵, Jolanta Grydehøj², Inger Marie Jensen Hansen², Michael Veedfald Sørensen², Stavros Chrysidis², Birgitte Lange Andersen², Natalia Manilo², Mette Klarlund², Lis Smedegaard Andersen², Henrik Nordin², Salome Kristensen², Jesper Nørregaard² and Merete Lund Hetland¹, ¹Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ²The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Dep. of Rheumatology, King Christians Hospital for Rheumatic Diseases, Copenhagen, Denmark
Background/Purpose: According to national guidelines issued in May 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish…
Abstract Number: 1997 • 2016 ACR/ARHP Annual Meeting
Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
Bente Glintborg¹, Tina Marie Kringelbach¹, Estrid Høgdall¹, Inge Juul Sørensen², Dorte Vendelbo Jensen², Anne Gitte Loft³, Oliver Hendricks⁴, Inger Marie Jensen Hansen², Asta Linauskas², Salome Kristensen², Hanne Lindegaard⁵, Henrik Nordin², Nils Bolstad⁶, David Warren⁶, Johanna Gehin⁶, Guro Løvik Goll⁶, Kathrine Lederballe Grøn², Grith Eng², Christian Enevold¹, Claus Henrik Nielsen¹, Julia Sidenius Johansen¹ and Merete Lund Hetland¹, ¹Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ²The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ³Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁴Dep. of Rheumatology, King Christians Hospital for Rheumatic Diseases, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ⁶Department of Medical Biochemistry, OUS-Radiumhospitalet and Diakonhjemmet Sykehus, Oslo, Norway
Background/Purpose: According to national guidelines issued in 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].